NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

Home・Akciju saraksts・Roche Holding AG

Roche Holding AG

Atvērts

SektorsVeselības aprūpe

370.8 1.26

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

362.8

Max

369.6

Galvenie mērījumi
By Trading Economics
Ienākumi	1.8B 5.5B
Pārdošana	15B 31B
P/E Sektora vidējais	23.041 108.767
Dividenžu ienesīgums	2.63
Peļņas marža	17.892
Darbinieki	103,249
EBITDA	5.1B 12B

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.63% 2.21%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	5.3B 294B
Iepriekšējā atvēršanas cena	369.54
Iepriekšējā slēgšanas cena	370.8

Ziņu noskaņojums

By Acuity

100%

333 / 352 Rangs Healthcare

Roche Holding AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. janv. 10:07 UTC

Peļņas

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

2026. g. 29. janv. 07:07 UTC

Peļņas

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

2025. g. 18. nov. 11:04 UTC

Galvenie tirgus virzītāji

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

2025. g. 23. okt. 09:32 UTC

Peļņas

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

2025. g. 23. okt. 05:54 UTC

Peļņas

Roche Raises Full-Year Earnings Outlook

2026. g. 3. marts 07:22 UTC

Tirgus saruna

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2026. g. 2. marts 14:21 UTC

Tirgus saruna

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

2026. g. 29. janv. 11:40 UTC

Tirgus saruna

Peļņas

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

2026. g. 29. janv. 06:05 UTC

Peļņas

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

2026. g. 29. janv. 06:04 UTC

Peļņas

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

2026. g. 29. janv. 06:03 UTC

Peļņas

Roche Issues 2026 View

2026. g. 29. janv. 06:02 UTC

Peļņas

Analysts Saw 2025 Core EPS at CHF19.70

2026. g. 29. janv. 06:02 UTC

Peļņas

Roche: 2025 Core EPS CHF19.46

2026. g. 29. janv. 06:01 UTC

Peļņas

Analysts Had Seen 2025 Sales At CHF61.47B

2026. g. 29. janv. 06:01 UTC

Peļņas

Roche 2025 Sales CHF61.52B

2026. g. 28. janv. 11:22 UTC

Peļņas

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

2026. g. 27. janv. 11:31 UTC

Tirgus saruna

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

2026. g. 27. janv. 11:24 UTC

Tirgus saruna

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

2026. g. 27. janv. 09:30 UTC

Tirgus saruna

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

2026. g. 27. janv. 07:52 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Roche Obesity Study Data Look Encouraging -- Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026. g. 12. janv. 14:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Pharma Sector Can Spend Big on M&A -- Market Talk

2025. g. 22. dec. 08:48 UTC

Tirgus saruna

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

2025. g. 19. nov. 12:47 UTC

Tirgus saruna

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

2025. g. 10. nov. 12:16 UTC

Tirgus saruna

Peļņas

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

2025. g. 23. okt. 09:19 UTC

Tirgus saruna

Peļņas

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

2025. g. 23. okt. 09:11 UTC

Tirgus saruna

Peļņas

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

2025. g. 23. okt. 05:09 UTC

Peļņas

Roche 3Q Sales Up 6% At CER

2025. g. 23. okt. 05:07 UTC

Peļņas

Roche 3Q Sales CHF14.92B

2025. g. 23. okt. 05:07 UTC

Peļņas

Analysts Had Seen 3Q Sales At CHF15.17B

Salīdzinājums

Cenas izmaiņa

Roche Holding AG Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Roche Holding AG — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

333 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.